| abstract |
Disclosed is are 4-phenylamino-2-arylamino-pyrimidine compounds of formula 1 where R1 and R2 together form an optionally substituted 5-6 membered aryl, heteroaryl or heterocyclis ring comprising 1-3 nitrogen atoms. The rest of the substituents are as described in the specification. Also disclosed is a pharmaceutical composition containing a compound of formula 1; a combination containing a compound of formula 2 and a chemotherapeutic agent and the use of a compound of formula 2 for producing a medicament for treating a condition mediated by anaplastic lymphoma kinase, and optionally the medicament is formulated for combination with a second therapeutic agent, wherein said condition is an autoimmune disease, a transplantation disease, an infectious disease, a cell proliferative disorder; and optionally the medicament is formulated for combination with a second therapeutic agent, wherein said cell proliferative disorder is lymphoma, osteosarcoma, melanoma, non-small cell lung carcinoma, neuroblastoma or a tumour selected from breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine and gastrointestinal tumour. |